These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 14104035)

  • 1. [RESEARCH ON THE ANTIRENAL AUTOANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS].
    MANGANOTTI G; CAPITANI G; GADDONI G
    Arch Ital Dermatol Venereol Sessuol; 1963 Oct; 32():100-8. PubMed ID: 14104035
    [No Abstract]   [Full Text] [Related]  

  • 2. Autoantibodies against complement components in systemic lupus erythematosus - role in the pathogenesis and clinical manifestations.
    Hristova MH; Stoyanova VS
    Lupus; 2017 Dec; 26(14):1550-1555. PubMed ID: 29092674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [IMMUNOLOGICAL ASPECTS OF COLLAGEN DISEASES].
    Tidsskr Nor Laegeforen; 1964 Jan; 84():63-7. PubMed ID: 14101802
    [No Abstract]   [Full Text] [Related]  

  • 4. [Relation between various autoimmune antibodies and serum complement levels in patients with systemic lupus erythematosus].
    Okumura N; Kumagai T; Kameko M; Kanai M
    Rinsho Byori; 1986 Aug; 34(8):967-72. PubMed ID: 3784036
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetics of systemic lupus erythematosus.
    Arnett FC; Reveille JD
    Rheum Dis Clin North Am; 1992 Nov; 18(4):865-92. PubMed ID: 1455048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenic role of auto-antibodies against complement components in systemic lupus erythematosus.
    Daha MR
    Lupus; 2008 May; 17(5):385-8. PubMed ID: 18490413
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical application of protein biomarkers in lupus erythematosus and lupus nephritis.
    Qi S; Chen Q; Xu D; Xie N; Dai Y
    Lupus; 2018 Sep; 27(10):1582-1590. PubMed ID: 29720035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of systemic lupus erythematosus with antimetabolites. Relations between the clinical course and immunological reactions].
    Cruchaud A; Pometta D; Rousso C
    Helv Med Acta; 1967; 34(1):Suppl:141-2. PubMed ID: 5301522
    [No Abstract]   [Full Text] [Related]  

  • 9. The complement system in systemic lupus erythematosus: an update.
    Leffler J; Bengtsson AA; Blom AM
    Ann Rheum Dis; 2014 Sep; 73(9):1601-6. PubMed ID: 24845390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus.
    Holers VM
    J Clin Invest; 2004 Sep; 114(5):616-9. PubMed ID: 15343378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biological diagnosis of systemic lupus erythematosus].
    Hilliquin P; Weill BJ
    Ann Med Interne (Paris); 1991; 142(7):515-20. PubMed ID: 1789530
    [No Abstract]   [Full Text] [Related]  

  • 12. [Relation between immune complexes, anti-DNA antibodies and complement in lupus nephropathy].
    Pastore A; Manno C; Losuriello V; Vox E; Schena FP
    Minerva Nefrol; 1981; 28(4):503-8. PubMed ID: 7339520
    [No Abstract]   [Full Text] [Related]  

  • 13. [Intervention of heparin in immunological phenomena: reversibility of the nuclear antigen and antinuclear antibody reaction in systemic lupus erythematosus].
    Bardare M; Menghi P
    Boll Soc Ital Biol Sper; 1965 Jul; 41(13):713-5. PubMed ID: 4164914
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunologic factors and clinical activity in systemic lupus erythematosus.
    Schur PH; Sandson J
    N Engl J Med; 1968 Mar; 278(10):533-8. PubMed ID: 4866347
    [No Abstract]   [Full Text] [Related]  

  • 15. Humoral markers of active Epstein-Barr virus infection associate with anti-extractable nuclear antigen autoantibodies and plasma galectin-3 binding protein in systemic lupus erythematosus.
    Rasmussen NS; Nielsen CT; Houen G; Jacobsen S
    Lupus; 2016 Dec; 25(14):1567-1576. PubMed ID: 27084029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of celiac disease autoantibodies in patients with systemic lupus erythematosus.
    Rensch MJ; Szyjkowski R; Shaffer RT; Fink S; Kopecky C; Grissmer L; Enzenhauer R; Kadakia S
    Am J Gastroenterol; 2001 Apr; 96(4):1113-5. PubMed ID: 11316156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the relationship between complement and systemic lupus erythematosus?
    Podrebarac TA; Goldstein R
    J Rheumatol; 1998 Nov; 25(11):2062-4. PubMed ID: 9818645
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical observations on C3 and CH50 in the serum of patients with systemic lupus erythematosus].
    Jin A
    Zhonghua Yi Xue Za Zhi; 1984 Jan; 64(1):36-8. PubMed ID: 6430492
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of three major target molecules of IgM antilymphocyte autoantibodies in systemic lupus erythematosus.
    Minota S; Winfield JB
    J Immunol; 1987 Dec; 139(11):3644-51. PubMed ID: 3500225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies against cell membrane constituents in systemic lupus erythematosus and related diseases. I. Cytotoxic effect of serum from patients with systemic lupus erythematosus (SLE) for allogeneic and for autologous lymphocytes.
    Stastny P; Ziff M
    Clin Exp Immunol; 1971 Apr; 8(4):543-50. PubMed ID: 5103550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.